What is the treatment for shigellosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 10, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Shigellosis

Ciprofloxacin 500 mg twice daily for 3-7 days is the preferred first-line treatment for shigellosis in adults, based on current CDC recommendations and FDA approval for this indication. 1, 2

Initial Antibiotic Selection

The choice of first-line antibiotic must be guided by local antimicrobial susceptibility patterns, as multiresistant Shigella strains are now widespread globally. 3, 1 When local resistance patterns are unknown or for travel-acquired cases, fluoroquinolones should be prioritized as first-line therapy. 1

First-Line Options for Adults:

  • Ciprofloxacin: 500 mg twice daily for 3-7 days (preferred agent) 1, 2
  • TMP-SMX: 160 mg TMP/800 mg SMX twice daily for 5 days (only if strain is susceptible) 3, 1
  • Azithromycin: 500 mg on day 1, then 250 mg daily for 4 days (for resistant strains) 1, 4

First-Line Options for Children:

  • TMP-SMX: 10 mg/kg/day TMP and 50 mg/kg/day SMX in two divided doses for 5 days (if susceptible) 3, 1
  • Azithromycin: Same dosing as adults, adjusted by weight 1

Important caveat: Fluoroquinolones are not FDA-approved for children, pregnant women, or lactating women, despite their high efficacy. 3, 1 For these populations, azithromycin or ceftriaxone should be considered as alternatives. 1

Treatment Algorithm and Monitoring

Assess clinical response within 48 hours of initiating therapy. 3, 1 If no clinical improvement occurs (persistent dysentery, fever >37.8°C, or >6 stools/day), change to an alternative antibiotic immediately. 3, 1

If no improvement occurs after an additional 2 days on the second antibiotic, refer the patient for stool microscopy to rule out amebiasis, as amebic dysentery is frequently misdiagnosed as shigellosis. 3, 1, 5 At this stage, resistant shigellosis remains more likely than amebiasis, but microscopic examination for Entamoeba histolytica trophozoites is essential. 3, 5

Alternative Agents for Resistant Strains

When first-line agents fail or resistance is documented:

  • Nalidixic acid: 55 mg/kg/day in four divided doses for 5 days 3
  • Tetracycline: 50 mg/kg/day in four divided doses for 5 days 3
  • Ceftriaxone: Effective for multidrug-resistant strains 6, 7

Special Clinical Situations

Shigella Bacteremia:

Extend treatment duration to 14 days using the same antimicrobial agents. 1

HIV-Infected Patients:

All HIV-associated Shigella infections require treatment due to higher complication risk. 1 Be aware that HIV-infected persons have higher rates of adverse effects from TMP-SMX. 1

Food Service/Healthcare Workers:

Follow-up stool cultures are required before return to work, even with complete clinical response. 1 For other patients, follow-up cultures are not necessary if complete clinical improvement is demonstrated. 1

Critical Pitfalls to Avoid

Do not use mass prophylaxis or prophylaxis of family members—WHO explicitly does not recommend this as a control measure for shigellosis. 3, 1 The single exception is in refugee settings with transmission rates >15% and adequate resources, where single-dose doxycycline for immediate family members may be considered. 1

Do not use antimotility agents—these are contraindicated in shigellosis. 6

Do not delay switching antibiotics—the 48-hour rule for assessing response is critical, as Shigella can rapidly acquire resistance during treatment. 3, 1

Supportive Care

Oral rehydration therapy should be administered concurrently to prevent or correct dehydration. 6 Early refeeding during and after shigellosis is emphasized. 6 Dehydration is typically not severe and responds well to oral rehydration. 8

Resistance Surveillance

Periodic antibiotic susceptibility testing should be performed by reference laboratories, particularly in endemic and epidemic settings, as Shigella strains can rapidly acquire resistance. 3, 1, 7 Fluoroquinolone resistance is emerging globally, and azithromycin plus third-generation cephalosporins remain effective but require ongoing monitoring. 7

References

Guideline

Treatment of Shigella Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Amebic Dysentery Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

An evaluation of current shigellosis treatment.

Expert opinion on pharmacotherapy, 2003

Research

Increasing antimicrobial resistance--an emerging problem in the treatment of shigellosis.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2007

Research

Shigella infections.

Clinics in gastroenterology, 1979

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.